Education
About Us
Working with TipRanks
Follow Us
Camurus AB (SE:CAMX)
:CAMX
Top Page
Camurus AB
(OTC:CAMX)
68Neutral
Camurus AB (CAMX) vs. S&P 500 (SPY)
Market Cap
$36.83B
Dividend YieldN/A
Average Volume (3M)78.28K
Price to Earnings (P/E)84.6
Beta (1Y)0.72
Revenue Growth8.78%
EPS Growth-5.57%
CountrySE
Employees238
SectorHealthcare
Sector Strength39
IndustryBiotechnology
Share Statistics
EPS (TTM)3.35
Shares Outstanding58,879,017
10 Day Avg. Volume98,985
30 Day Avg. Volume78,278
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)10.42
Price to Sales (P/S)0.00
P/FCF Ratio95.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Camurus AB Business Overview & Revenue Model
Company DescriptionCamurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
How the Company Makes MoneyCamurus AB generates revenue through the sales and licensing of its pharmaceutical products. The company's proprietary FluidCrystal technology serves as a platform for developing long-acting injectable treatments, which are licensed to other pharmaceutical companies, thereby generating licensing fees and royalties. Additionally, Camurus markets its own products, such as Buvidal, which is used for the treatment of opioid dependence, directly contributing to its revenue. Significant partnerships with healthcare providers and pharmaceutical companies also play a crucial role in extending the reach of its products, further supporting its financial performance.
Camurus AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.87B | 1.72B | 956.34M | 600.57M | 336.00M | Gross Profit |
| 1.74B | 1.59B | 853.08M | 515.22M | 300.71M | EBIT |
| 469.17M | 532.36M | 71.96M | -112.36M | -206.57M | EBITDA |
| 568.24M | 562.54M | 87.59M | -97.72M | -196.58M | Net Income Common Stockholders |
| 428.39M | 431.44M | 55.55M | -90.45M | -167.26M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.85B | 1.19B | 565.54M | 411.57M | 461.79M | Total Assets |
| 3.76B | 1.91B | 1.31B | 1.08B | 1.04B | Total Debt |
| 17.04M | 24.51M | 26.22M | 25.66M | 25.48M | Net Debt |
| -2.84B | -1.17B | -539.32M | -385.92M | -436.31M | Total Liabilities |
| 467.33M | 414.82M | 310.82M | 232.99M | 196.66M | Stockholders Equity |
| 3.29B | 1.49B | 994.67M | 848.91M | 847.44M |
| Cash Flow | Free Cash Flow | |||
| 358.62M | 596.75M | 99.29M | -148.37M | -242.16M | Operating Cash Flow |
| 387.99M | 606.88M | 101.20M | -143.43M | -238.83M | Investing Cash Flow |
| -29.37M | -10.13M | 5.38M | -4.94M | -3.33M | Financing Cash Flow |
| 1.30B | 28.76M | 43.70M | 98.90M | 347.85M |
Camurus AB Technical Analysis
Positive
621.50
Price Trends
596.82
Positive
596.85
Positive
613.43
Positive
Market Momentum
16.62
Negative
53.28
Neutral
41.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CAMX, the sentiment is Positive. The current price of 621.5 is above the 20-day moving average (MA) of 610.17, above the 50-day MA of 596.82, and above the 200-day MA of 613.43, indicating a bullish trend. The MACD of 16.62 indicates Negative momentum. The RSI at 53.28 is Neutral, neither overbought nor oversold. The STOCH value of 41.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CAMX.
Camurus AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Performance Comparison
SE:CAMX
Camurus AB
621.50
54.50
9.61%
SE:HNSA
Hansa Biopharma AB
25.02
-12.98
-34.16%
DE:B9A
BioArctic AB Class B
16.40
-1.43
-8.02%
DE:8F8
SynAct Pharma AB
1.64
1.05
177.97%
DE:7XB
Xbrane Biopharma AB
0.02
0.00
0.00%
DE:6XP
Xspray Pharma AB
3.00
-1.14
-27.54%
Camurus AB Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q3-2024)
| % Change Since: 5.97%|
Next Earnings Date:Jul 17, 2025
Earnings Call Sentiment Positive
The earnings call presented strong financial performance and growth in key product sales, along with a solid cash position. However, challenges such as the FDA's CRL and increased operating expenses were noted. The positive aspects of growth and profitability were more pronounced, leading to an optimistic outlook.Q3-2024 Updates
Positive Updates
Record Revenue Growth
Camurus achieved a revenue growth of 38% year-on-year, reaching SEK 480 million, excluding a one-time revenue in 2023.
Increased Profitability
Profit before tax increased by 125% to SEK 165 million in Q3, excluding the one-time milestone.
Strong Cash Position
Cash position increased to SEK 2.75 billion, with no debt.
Buvidal and Brixadi Sales Growth
Buvidal sales grew by 22% year-on-year to SEK 421 million, and Brixadi net sales increased by 39% quarter-on-quarter, resulting in a SEK 58 million royalty contribution.
Positive R&D Advancements
Advanced R&D pipeline with positive Phase III results from the ACROINNOVA 2 study and progress in U.S. NDA labeling.
Negative Updates
FDA Complete Response Letter
Received a CRL from the FDA due to cGMP inspection at a third-party manufacturer, pending classification.
Slight Market Slowdown
The third quarter showed a slight slowdown in market growth, attributed to seasonal factors.
Increased Operating Expenses
Total OpEx reached SEK 304 million, a 21% increase versus the prior year, driven by marketing and distribution investments.
Company Guidance
During the Q3 2024 earnings call for Camurus (CAMX.ST), the company provided an optimistic update on its financial and operational performance. Revenue in the third quarter increased by 38% year-on-year to SEK 480 million, with an impressive profit before tax surge of 125% to SEK 165 million. The quarter also saw Buvidal sales climb by 22% to SEK 421 million, while Brixadi net sales in the U.S. rose by 39% quarter-on-quarter, contributing SEK 58 million in royalties. The company's gross margin reached 93%, and its cash position improved to SEK 2.75 billion, maintaining a debt-free status. The company revised its full-year 2024 outlook upwards, anticipating total revenue between SEK 1,810 million and SEK 1,880 million, and a profit before taxes in the range of SEK 450 million to SEK 510 million. R&D advancements were highlighted by positive Phase III results and ongoing regulatory progress, despite a CRL from the FDA due to a cGMP inspection issue. Camurus remains focused on meeting its 2027 vision, buoyed by strong year-to-date performance and promising Q4 expectations.Camurus AB Corporate Events
Camurus Appoints New CFO to Drive Growth and Diversification
May 14, 2025
Camurus has appointed Anders Vadsholt as its new Chief Financial Officer, effective July 1, 2025. Vadsholt brings significant financial and M&A experience from the biotech and pharmaceutical sectors, having previously served as CFO for Orphazyme A/S and Topotarget A/S. This strategic appointment is expected to support Camurus’ continued growth and diversification, enhancing its position in the biopharmaceutical industry. The transition is set to be smooth, with outgoing CFO Jon Garay Alonso remaining until August to facilitate the change.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.